Insulin degludec (Tresiba)
Daily ultra-long-acting basal insulin analog · insulin class · sc daily · Novo Nordisk
Top dose
titrated
HbA1c reduction
-1.30%
at week 52 · treatment policy
AE discontinuation
2.0%
Status
approved
Pivotal trial
- Trial
- BEGIN (insulin-naive)
- Indication
- type 2 diabetes
- Duration
- 52 weeks
- ClinicalTrials.gov
- NCT00972283
- Sponsor
- Novo Nordisk
Notes
Established once-daily ultra-long basal analog; included as the daily-insulin benchmark the once-weekly entrants are measured against. Hypoglycemia profile, not AE-led discontinuation, drives differentiation.